Evaluation of Nexavar® in the Treatment of Hepatocellular Carcinoma (HCC)
A Survey of 33 Oncologists and 17 Hepatologists
November 2008
Deliverable: Survey with key findings.
Study Description:
|
Topic |
Hepatocellular Carcinoma (HCC) |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Oncology and Heptatology |
|
Region |
EU |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: Approximately 15 minutes’ duration Size: 50 total respondents Fielding Dates: Fielded online from October 31, 2008 to November 7, 2008 |
Objectives:
To determine level of familiarity and usage of sorafenib (Nexavar®) in the treatment of hepatocellular carcinoma (HCC) among hepatologists and oncologists in
§ Determine the volume of HCC patients at each severity level of the disease
§ Identify when European physicians first became aware of and first used Nexavar
§ Assess opinions of Nexavar in the treatment of HCC
§ Evaluate the usage of Nexavar in the treatment of both early stage and advanced HCC; including volume of patients in various subsets, changes in volume since initial use, duration of therapy, and dosing
§ Determine volume of Nexavar patients needing a dose reduction or discontinuing the drug and reasons for the reduction or discontinuation
§ Predict future trends in the usage of Nexavar and reasons behind any anticipated changes
§ Explore potential impact of STORM trial data on Nexavar usage in the adjuvant population
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
ONYX Pharmaceuticals, Inc./ Bayer HealthCare |
ONXX/BAYRY |
Nexavar® (sorafenib) |
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria |
§ European physicians: Germany, France, Italy, and Spain § 2 to 30 years of experience post-training § Minimum of 50% professional time spent in clinical practice § Treats at least 50 HCC patients per year § Prescribes Nexavar to at least 5 patients per year § Nexavar must be most frequently prescribed treatment |
Print Abstract
For additional information on this study or to purchase, please call:
|
Survey
Hepatology |